Reply to: Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer

Bardia A, Pistilli B, Rugo H. Reply to: Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer. J Clin Oncol. 2025 Mar 28:JCO2402833. doi: 10.1200/JCO-24-02833. Epub ahead of print. PMID: 40153734.


Related Posts